Project Grant HT94252410263
Award Date
6/1/24
Completion Date
5/31/26
Dollars Obligated
$1M
Federal Agency
Defense Health Agency
Awardee
Metis Foundation (CYYCLBFLP125)
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
San Antonio, TX 78216, USA
Similar Awards
This $1,845,076 federal Project Grant award, issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports the Metis Foundation's research on novel therapeutics targeting innate immune responses for treating multiple organ failure in severe polytrauma during prolonged casualty care. The award, effective from November 1, 2024 to October 31, 2027, will enable the Metis Foundation, a non-profit organization based in San Antonio, Texas, to...
The federal Project Grant award, valued at $1,927,373.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports research conducted by the Fred Hutchinson Cancer Center in Seattle, Washington to develop targeted therapies for metastatic prostate cancers classified by subtypes of DNA repair deficiency. The research aims to transform healthcare for military service members and the broader public by investigating...
The federal Project Grant award of $909,510.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports precision therapy research aimed at eradicating brain metastatic breast cancer. The primary awardee, The Geneva Foundation, is a 501(c)3 non-profit organization focused on providing medical research, development, clinical trials, and support services to the U.S. federal government, particularly for military...
This Project Grant award for $366,000.00, awarded on Sep 30, 2024 by the Defense Health Agency, supports research conducted by The Geneva Foundation to identify functional structural variants that influence therapy outcomes for human castration-resistant prostate cancer. The award is funded through the Military Medical Research and Development program (CFDA 12.420), which supports a broad range of biomedical research initiatives to improve health outcomes for military service members,...
The Defense Health Agency awarded a $1,036,233 Project Grant to the Fred Hutchinson Cancer Research Center under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from July 2021 through June 2024 to develop more precise molecular classification and targeted treatment of metastatic castration-resistant prostate cancer (MCRPC) through multi-omic analysis of circulating tumor DNA (ctDNA). By leveraging ctDNA analysis, the research aims to transform...
This Project Grant award from the U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $1,561,500.00 to Health Research, Inc. at Roswell Park Cancer Center to conduct research targeting prostate cancer metabolic vulnerabilities in the bone microenvironment. The goal is to develop new approaches to circumvent lethal metastatic disease. The 3-year award period runs from September 15, 2023 to September 14, 2026. As a non-profit research organization,...
The Department of the Army Medical Command awarded a $520,751 Project Grant to the Veteran Research And Education Foundation Of ST Louis through the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from August 1, 2022 to July 31, 2026 to improve outcomes for prostate cancer patients based on comorbidities, with the goal of developing personalized medicine approaches. Through this award, the Foundation will conduct research to investigate medical...
The federal Project Grant award of $1,578,836.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports the Fred Hutchinson Cancer Center (doing business as Seattle Cancer Care Alliance) in developing and exploiting a third-generation prostate cancer dependency map to identify cancer vulnerabilities and treatment targets. The award, which runs from August 1, 2024 to July 31, 2027, will enable the research organization to conduct innovative...
The U.S. Defense Health Agency awarded a $1,513,169 Project Grant to Health Research, Inc. to support the "LEVERAGING POLYAMINE METABOLISM TO TARGET EPIGENOMIC ADAPTABILITY AND LINEAGE PLASTICITY IN PROSTATE CANCER" research project under the Military Medical Research and Development program (CFDA 12.420). This 3-year grant, beginning on April 1, 2024, aims to develop innovative approaches for treating prostate cancer by targeting tumor metabolism and epigenetic mechanisms. As a...
This federal Project Grant award in the amount of $1,229,700.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award is supporting research conducted by the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts focused on "DISSECTION OF MOLECULAR ASSOCIATIONS OF RESPONSE TO NEOADJUVANT ANTIANDROGEN THERAPIES IN HIGH-RISK LOCALIZED PROSTATE CANCER." The 4-year research project aims to advance the...